Moffitt mathematical model predicts patient outcomes to adaptive therapy

April 09, 2020

TAMPA, Fla. - Prostate cancer is the most common malignancy among men in the United States. It is also the second most common cause of cancer-related deaths. Despite improved treatments for prostate cancer, many patients with advanced disease eventually develop drug resistance. Researchers in the Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center believe that adaptive treatments based on evolutionary principles may be an effective approach to prostate cancer treatment by preventing the development of drug resistance and prolonging patient survival. In an article published today in Nature Communications, the research team provides a closer look at a model and data showing that individual patient alterations in the prostate-specific antigen (PSA) biomarker early in treatment can predict outcomes to later treatment cycles of adaptive therapy. These models could eventually be used to devise patient specific treatments according to changing tumor growth and biomarker patterns.

Patients with prostate cancer are commonly treated with radiation therapy or surgery followed by androgen deprivation therapy (ADT) at the highest tolerated dose to kill as many cancer cells as possible. While initial responses to this approach are often effective, eventually patients develop drug resistance and their tumors recur.

"Continuous treatment, by maximally selecting for resistant phenotypes and eliminating other competing populations, may actually accelerate the emergence of resistant populations - a well-studied evolutionary phenomenon termed competitive release," said study author Heiko Enderling, Ph.D., associate member of Moffitt's Department of Integrated Mathematical Oncology.

Enderling and his team, in collaboration with scientists from Duke University, University of North Carolina and Arizona State University, believe that instead of using a continuous maximum tolerated dose, a better approach would be to use adaptive therapy with intermittent dosing. This treatment strategy is based on changing patterns of biomarker levels in individual patients; treatment may increase or decrease or even be temporarily halted according to patient-specific markers and tumor dynamics.

"Fully harnessing the potential of intermittent prostate cancer therapy requires identifying ADT resistance mechanisms, predicting individual responses and determining potentially highly patient-specific, clinically actionable triggers for pausing and resuming intermittent-ADT cycles," said study lead author Renee Brady, Ph.D., a post-doctoral fellow in the Department of Integrated Mathematical Oncology at Moffitt. She added this seemingly daunting challenge could be overcome by advances in mathematical modeling.

Previous mathematical models are based on a variety of different resistance mechanisms and include numerous variables; however, they do not completely predict patient responses and outcomes to intermittent ADT. The Moffitt team built its model on a different theory; they hypothesized that prostate cancer stem cells contribute to tumor differences between patients and treatment failure. They devised a model that simulated and predicted the dynamics of three factors during intermittent ADT: prostate cancer cells, differentiated cancer cells and the biomarker PSA. The researchers validated their model to show that stem cells are highly associated with intermittent ADT resistance. Patients who are resistant are more likely to have stem cells with higher rates of self-renewal, subsequently leading to higher levels of prostate cancer stem cells and changing levels of the biomarker PSA during each treatment cycle.

The researchers combined their model with clinical data from a study of intermittent-ADT therapy and demonstrated that it predicted the development of patient resistance with 89% accuracy. Furthermore, they demonstrated that by using this model, they could predict which patients would benefit from alternative treatments.

These results demonstrate the feasibility of using mathematical models to guide adaptive therapy clinical trials and provide more personalized treatment options to improve patient outcomes. "This ability to learn from early treatment cycles and predict subsequent responses adds an essential degree of personalization and flexibility to a cancer treatment protocol," said Enderling.
-end-
This study was supported by the National Institutes of Health, the Ocala Royal Dames for Cancer Research, Inc. and The Jayne Koskinas Ted Giovanis Foundation for Health and Policy.

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.

H. Lee Moffitt Cancer Center & Research Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.